19 June 2013
Keywords: new, data, confirms, gsk, requip, potential, therapy
Article | 03 May 2004
GlaxoSmithKline's Requip (ropinirole) produces long-term improvements in symptoms of restless legs syndrome, as well as health-related quality of
life (HRQoL) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 May 2004
18 June 2013
© 2013 thepharmaletter.com